MolecularHealth Partners with GATC Biotech for Genetic Sequencing Technology and Expertise

14-Jan-2014 - Germany

MolecularHealth announced a unique agreement with GATC Biotech. GATC Biotech will provide protocols, support and extensive training of MolecularHealth’s laboratory staff. Additionally, MolecularHealth will use GATC Biotech’s LIMS (Laboratory Information Management System) in itsnewly opened clinical lab. These contributions will complement MolecularHealth’s next generation sequencing offerings and its proprietary TreatmentMAP™ oncology treatment decision support platform.

“In preparation for the launch of TreatmentMAP in Q1 of this year, it’s essential that we put the best protocols in place for our lab,” said Lloyd Everson, M.D., CEO of MolecularHealth. “GATC Biotech has decades of experience in sequencing technology and services, and a standardized, validated, automated process. Their proven expertise will be invaluable to our team, as we work to provide personalized, actionable information to cancer patients and their medical teams.”

“GATC Biotech is a global leader in genomic sequencing and we are pleased to partner with MolecularHealth on this strategic collaboration to improve life for cancer patients,” said Peter Pohl, CEO of GATC Biotech. “We are convinced that our know-how, combined with MolecularHealth’s data interpretation, will pave the way for personalized medicine by enabling substantiated decisions about individual cancer care” he adds.

MolecularHealth’s lab, located in Houston metro area, will offer two laboratory-developed tests: a targeted gene panel of more than 500 known cancer genes, and whole exome sequencing of the tumor genome. The company, backed by Dietmar Hopp, co-founder and former chairman and CEO of SAP, offers an end-to-end service that walks patients and their healthcare providers through the molecular diagnostic process—collecting tumor samples, analyzing the samples, and interpreting the results using a unique analytics platform—all to generate safer and more targeted cancer treatment choices. As part of its offering, MolecularHealth will provide patients, oncologists and pathologists with complete logistical support and help navigating insurance reimbursement for recommended treatments.

Other news from the department business & finance

Most read news

More news from our other portals

Under the magnifying glass: The world of microscopy

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 whitepaper
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 whitepaper